Skip to main content

Table 2 Lupus and scleroderma disease presentation according to autoantibody serology, manifestations and tests

From: DNA methylation similarities in genes of black South Africans with systemic lupus erythematosus and systemic sclerosis

Systemic Lupus Erythematosus (SLE)

Systemic Sclerosis (SSc)

(n = 30)

(n = 30)

Autoantibodies, manifestations and tests

SLEDAI score

Autoantibodies and manifestations

dcSSC(n = 14)

lcSSc(n = 5)

“other” (e.g. UCTD, morphea, Reynaud’s) (n = 3)

Unclassified(n = 7)

Mild, score <10(n = 21)

Moderate, score 10–20 (n = 3)

Severe, score >20 (n =0)

unscored (n = 6)

ANA positive (n = 22) 73 %

13

6

5

n/a

ANA positive (n = 29) 97 %

20

3

0

6

ACA positive (n = 6) 20 %

3

2

1

n/a

DLE positive (n = 19) 63 %

15

2

0

3

ATA positive (n = 2) 7 %

2

0

0

n/a

Coombs’ test positive (n = 14) 47 %

9

3

0

3

ILD (n = 10) 33 %

6

1

3

n/a

  1. Abbreviations: ACA, anticentromere autoantibody; ANA, anti-nuclear antibodies; ATA, Antitopoisomerase antibodies; Coombs’ test, detects presence of antibodies that act against the surface of red blood cells, indicates haemolytic anaemia; DLE, Discoid lupus erythematosus; ILD, interstitial lung disease, indicator of direct pulmonary involvement, and leading cause of death; dcSSc, diffuse cutaneous systemic sclerosis; lcSSc, limited cutaneous systemic sclerosis; UCTD, undifferentiated connective tissue disease; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; n/a, results not available.
Back to article page

Journal of Biomedical Science

ISSN: 1423-0127